Biogen's aducanumab for Alzheimer's accepted onto EMA scheme

The European Medicines Agency (EMA) has accepted aducanumab, an investigational treatment for early Alzheimer’s disease being developed by US biotech major Biogen (Nasdaq: BIIB), into its Priority Medicines (PRIME) program.

This scheme, launched in March, aims to bring treatments to patients faster by enhancing the EMA’s support for the development of investigational medicines for diseases without available treatment or in need of better treatment options.

Alfred Sandrock, chief medical officer at Biogen, said: “Alzheimer’s disease is a debilitating condition affecting a growing number of patients and their loved ones, and there is an urgent need for new effective treatment for this disease."